Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; NYU School of Medicine to examine multiple aspects of SM-88 mechanisms; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: tymeinc.com
BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr. Van Tornout will provide leadership and direction for all medical and related preclinical programs in development. He will be replacing Dr. Giuseppe Del Priore. “On behalf of the board of directors, we truly appreciate Giuseppe’s many contributions towards advancing our programs and we wish him continued success in his future endeavors,” said Richie Cunningham, TYME’s CEO. Dr. Van Tornout brings
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
-- Combined Company to Trade on Nasdaq Under Ticker "SYRS" ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pu
-- Combined Company to Trade on Nasdaq Under Ticker "SYRS" -- -- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pursuant to which a direct, wholly owned subsidiary of Syros will merge with
BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) ("Tyme" or the "Company"), today announced that independent proxy advisory firms Glass, Lewis & Co. ("Glass Lewis") and Institutional Shareholder Services Inc. ("ISS") have recommended that Tyme stockholders vote "FOR" the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. ("Syros") and "FOR" all other matters to be voted upon at the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for September 15, 2022 at 11:00 a.m., Eastern Time. ISS and Glass Lewis are leading independent, third-party proxy advisory firms who, among other services, provide pro
Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-dow
BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022. In March the Company announced that its Board of Directors decided to explore potential strategic options to enhance stockholder value, and this process is active and ongoing. The Company plans to provide an update upon completion of this process. Fourth Fiscal Quarter and Full Year 2022 Financial Results As of the quarter ended March 31, 2022, the Company had approximately $84.0 mi
BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value. The Company has engaged Moelis & Company LLC as its financial advisor and Faegre Drinker Biddle & Reath LLP as its legal advisor. On January 26, 2022, TYME announced the discontinuation of a randomized Phase II/III trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus (MPS) for patients with metastatic pancreatic cancer upon learning that the trial
– Industry veteran, Christine D. Baker, joins Board of Directors – Douglas A. Michels appointed Chairman of the Board TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced changes to its Board of Directors. Christine D. Baker Named to Board of Directors The Company is pleased to announce that Christine D. Baker has been appointed to TYME's Board of Directors. Ms. Baker brings over 30 years of experience in the biotech/pharmaceutical industry, with expertise in business development, commercialization, and drug development strategies. She is currently the Chief Business Officer
-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive breast cancer -- -- Poster presentation April 11, 1:30pm ET; abstract available online -- BEDMINSTER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the availability of the poster abstract, "SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor positive breast cancer," which was submitted by researchers from Georgetown University. The abstract will be pr
– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – On track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing's and other sarcoma types – Pursuing options to diversify the clinical pipeline – Well-capitalized position, with $92.0 million in cash and marketable securities as of December 31, 2021 – Company to host live conference call and webcast today, February 11, at 8:30 AM ET TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emer
TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 1286376 The webcast will be accessible on the Events & Presentations page of the Investors s
SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
Gainers Quotient (NASDAQ:QTNT) shares increased by 15.7% to $0.24 during Friday's pre-market session. The company's market cap stands at $32.5 million. Tyme Technologies (NASDAQ:TYME) stock moved upwards by 13.21% to $0.33. The market value of their outstanding shares is at $56.0 million. Landos Biopharma (NASDAQ:LABP) shares increased by 10.47% to $1.16. The company's market cap stands at $46.6 million. Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 9.06% to $1.34. The company's market cap stands at $41.4 million. Addex Therapeutics (NASDAQ:ADXN) shares rose 8.84% to $1.04. The market value of their outstanding shares is at $8.5 million. 9 Meters Biopharma (NASDAQ:
Gainers Kensington Capital Acquisition Corp. IV (NYSE:AMPX) rose 159.4% to $25.94 in pre-market trading after gaining 11% on Thursday. Applied Optoelectronics, Inc. (NASDAQ:AAOI) shares rose 31.2% to $3.28 in pre-market trading after the company announced the sale of its Chinese manufacturing facilities to Yuhan Optoelectronic Technology for $150 million. Fast Radius, Inc. (NASDAQ:FSRD) rose 11.1% to $0.5711 in pre-market trading. Fast Radius, last month, posted a Q2 loss of $0.29 per share. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) rose 11.7% to $0.8149 in pre-market trading after the company and Tyme Technologies announced stockholder approval of the merger agreement. The company a
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Friday after recording losses on Thursday. The Nasdaq 100 index dipped more than 200 points in the previous session following the release of several economic reports. The University of Michigan's consumer sentiment report for September is scheduled for release at 10:00 a.m. ET. After rising around 7 points in August, analysts expect consumer sentiment improving further by 1.7 points to 59.9 in September. Check out this: Volatility In Markets Increases As Nasdaq Tumbles 200 Points Futures for the Dow Jones Industrial Average dipped 262 points to 30,712.00 while the Standard & Poor’s 500 index futures fell 37 poi
With US stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: FedEx Corp (NYSE:FDX) issued preliminary results. The company said it now expects first-quarter revenue of approximately $23.2 billion and first-quarter adjusted earnings to be around $3.44 per share. FedEx has withdrawn its fiscal year 2023 earnings forecast. The company expects business conditions to weaken further in the second quarter. FedEx shares dipped 16.6% to $170.90 in the after-hours trading session. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) and Tyme Technologies, Inc. (NASDAQ:TYME) announced stockholder approval of the merger agreement. Syros also
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros (the "Merger"). At Syros' special meeting, Syros' stockho
Gainers Akero Therapeutics, Inc. (NASDAQ:AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Aditxt, Inc. (NASDAQ:ADTX) jumped 113.8% to close at $0.37. Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) surged 101% to close at $3.86 after a late Monday Form 4 filing showed multiple insider purchases of the stock. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) climbed 79.3% to close at $29.90 on Tuesday as the stock started trading on a 1-for-30 reverse split basis. 89bio, Inc. (NASDAQ:ETNB) shares rose 40% to close at $7.00. Analysts reportedly said Akero's NASH data co
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis. Akero Therapeutics, Inc. (NASDAQ:AKRO) shares climbed 111% to $25.88 after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) rose 47.4% to $2.83 after a late Monday Form 4 filing showed multiple insider purchases of the stock. 89bio, Inc. (NASDAQ:ETNB) shares gained 32.4% to $6.62. Analysts reportedly said Akero's NASH data could be a positive for the company's Pegoza program in NASH. VNET Group, Inc. (NASDAQ:VNET) surged 30.7% to $6.13 after
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average price of $2.03 - $2.07. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shares rose 35.6% to $0.9906 in pre-market trading after the FDA granted Syros Pharmaceuticals Orphan Drug Designation for the treatment of pancreatic cancer. Zovio Inc (NASDAQ:ZVO) rose 30.3% to $0.3074 in pre-market trading after declining over 5% on Monday. iBio, Inc. (NYSE:IBIO) rose 18.1% to $0.32 in pre-market trading after declining over 4% on Monday. American Rebel Holdings, Inc. (NASDAQ:AREB) rose 17.3% to $0.7798
Gainers Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average volume over the last 100 days. The company's market cap stands at $22.7 million. Avenue Therapeutics (NASDAQ:ATXI) stock rose 12.6% to $0.26. Trading volume for this security closed at 64.1K, accounting for 24.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.7 million. Aquestive Therapeutics (NASDAQ:AQST) stock increased by 10.39% to $1.38. Trading volume for this security closed at 188.7K, accounting for 20.0% of its average full-da
Gainers Exicure (NASDAQ:XCUR) shares increased by 97.0% to $3.92 during Wednesday's after-market session. This security traded at a volume of 1.0 million shares come close, making up 12.1% of its average volume over the last 100 days. The company's market cap stands at $19.4 million. Syros Pharmaceuticals (NASDAQ:SYRS) shares rose 39.89% to $1.23. Today's trading volume for this security ended up closing at 4.8 million shares, which is 673.0 percent of its average volume over the last 100 days. The company's market cap stands at $77.4 million. Motus GI Hldgs (NASDAQ:MOTS) stock moved upwards by 22.91% to $5.9. Motus GI Hldgs's trading volume hit 948.2K shares by close, accounting for 146.
Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-dow
– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – On track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing's and other sarcoma types – Pursuing options to diversify the clinical pipeline – Well-capitalized position, with $92.0 million in cash and marketable securities as of December 31, 2021 – Company to host live conference call and webcast today, February 11, at 8:30 AM ET TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emer
TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 1286376 The webcast will be accessible on the Events & Presentations page of the Investors s
– First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – – PanCAN Precision Promise trial to add five new sites in early 2022 – – Commenced preclinical initiative with Evotec, a global leader in drug development, to evaluate the potential of expanding our SM-88 platform to other indications – – Maintained a well-capitalized position, with $96.6 million in cash and marketable securities as of September 30 – – Company to host live conference call and webcast today, November 8, 2021, at 8:30 AM ET – TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME),
Company to report its second quarter fiscal 2022 financial results TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its second quarter 2022 financial results on Monday, November 8, 2021 at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Monday, November 8, 2021 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 5953454 The webcast will be accessible
– Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings – - Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus ("MPS") in metastatic HR+/HER2- breast cancer, with Georgetown University – - Granted U.S. patent claims covering use of tyrosine-based drug delivery method to treat cancer - –Appointed acting Chief Medical Officer Dr. Jan M. Van Tornout, and Chief Financial Officer, Frank Porfido - – Well-capitalized position, with $101.5 million in cash and marketable securities as of Q1 FY2022 - – Company to host liv
Company to report its first quarter fiscal 2022 financial results TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its first quarter 2022 financial results on Tuesday, August 10, 2021 at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Tuesday, August 10, 2021 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 4276767 The webcast will b
15-12G - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
POS AM - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
POS AM - TYME TECHNOLOGIES, INC. (0001537917) (Filer)